TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Microbiome Analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mitochondrial Function Analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Oxidative Stress Analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Metabolomics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Epigenetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total phosphate bound per gum piece fasting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: total phosphate bound per piece of gum post meal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sustained Virologic Response 12 weeks after EOT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events leading to permanent discontinuation of study drug
Endpoint domain: Adverse events/effects
Primary endpoint: tissue Doppler imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: E/Ea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of Major Adverse Events (MAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Office Systolic Blood Pressure (OBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Detection of intestinal metaplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of digestive system complications after operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Concentration of intestinal fatty acid-binding protein (I-FABP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: PCR negativity of HBV DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Participants With Febrile Reactions Post-dose 1
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Febrile Reactions Post-dose 2
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Febrile Reactions Post-dose 3
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Febrile Reactions Post-dose 4
Endpoint domain: Adverse events/effects
Primary endpoint: Glasgow Prognostic Score (GPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Dose-limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Hematology Abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: P2Y12 Reaction Units
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum plasma olaparib concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration time curve from zero to infinity (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration time curve from zero to the last measurable time point (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subharmonic Aided Pressure Estimation (SHAPE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulsated oxygen saturation (Sp02)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Oxygen inspired fraction (FiO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Blood gasometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum standardised uptake values (SUVmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discharge after 7 days
Endpoint domain: Mortality/survival
Primary endpoint: Exercise performance in the 20-km time trial
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Sidestream Dark Field (SDF) imaging variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional oral intake scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune persistence measured by anti-HAV and anti-HBs antibodies and GMCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adverse events with grade 3 or 4
Endpoint domain: Adverse events/effects
Primary endpoint: Heart rate (bpm) after CO2 insufflation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean arterial pressure (mmHg) after CO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Schirmer's test result
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ocular surface disease index (OSDI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in chronic ocular complication score (COCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from transplant-related mortality
Endpoint domain: Mortality/survival
Primary endpoint: Changes in depression levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in cardiovascular risk markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: adherence to treatment choice
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Birth outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Anti Xa Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protein Synthesis Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Subjective Response to Alcohol
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Neural Alcohol Cue Reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caregiver Strain
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Caregiver Self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: MCCB overall composite score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Most common health issues of community-dwelling elderly
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and type of suspected serious adverse drug reactions (SADRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Post Operative Pain Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Nucleated Cells Collected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of CD34+ Cells Collected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: activity of intestinal alkaline phosphatase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Objective Response Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posterior-superior contact
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Accurate Classification of Irreversible Airflow Obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Composite of death and new receipt of renal-replacement therapy
Endpoint domain: Mortality/survival
Primary endpoint: Differences in time trial performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differences in glucose concentration (GLU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Differences in lactate concentration (LA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Spouse Self-report of Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Spouse Self-report of Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Spouse Self-report of Resilience
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Facility delivery ratios
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of patients not independent at 90 days
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Fold Increase in Geometric Mean Titer (GMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: linear and volumetric wear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression/occurrence of acute heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Susceptibility changes in Streptococcus Pneumoniae
Endpoint domain: Adverse events/effects
Primary endpoint: Susceptibility changes in Staphylococcus Aureus
Endpoint domain: Adverse events/effects
Primary endpoint: Susceptibility changes in Haemophilus Influenzae
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline in cotinine level at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in smoking status at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shape and frequency of uterine contractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Serum concentrations of JNJ-54452840
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post operative 5 year survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Benefit of Bone-anchored hearing aid
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 24 hour ambulatory blood pressure measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Composite Event
Endpoint domain: Mortality/survival
Primary endpoint: Number of CVC infections
Endpoint domain: Adverse events/effects
Primary endpoint: Use of medical cannabis against chronic musculoskeletal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Authorization of medical cannabis by a physician
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percent Change in FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: serum 25-hydroxy vitamin D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in knowledge, beliefs, and actions regarding stress in children
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Recurrence of acquired thrombotic thrombocytopenic purpura (aTTP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Saliva cotinine concentration of mother
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Saliva cotinine concentration of infant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MCF (mm) by EXTEM activators
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in subjective perception of nasal ventilation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number and time of recurrences of therapeutic paracenteses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Dependence on renal-replacement therapy at 28 days in survivors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Overall Clinical Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum coenzyme Q10 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevention of Contrast-induced Nephropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mood state measures: Positive and Negative Affect Schedule (PANAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Successful operation of the Caverject Impulse Delivery System
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy rate of sentinel node identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Area Under the Curve (AUC) of Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adjusted Geometric Mean Concentration (GMC) of Clostridium Difficile Toxin A and Toxin B Specific Neutralizing Antibodies at Month 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Achieving Seroresponse for Clostridium Difficile Toxin A and Toxin B at Month 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Serious Adverse Events (SAEs) Through 6 Months After Last Study Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Marginal Bone Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regulatory T Cells (Tregs)/Total CD4+ Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in intraocular pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Platelet Inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Complete Epicardial and myocardial reperfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: National Institutes of Health Stroke Scale (NIHSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Estimated blood loss per mass of red blood cells lost
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: quality of response
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Palmoplantar Physician Global Assessment (ppPGA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monocular Photopic Distance Corrected Intermediate Visual Acuity (DCIVA) at 66 cm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monocular Photopic Distance Corrected Depth of Focus Assessed by the Mean Defocus Curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported Nicotine Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carbon Monoxide (CO)- Evaluated Nicotine Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nicotine Dependence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Momentary Craving
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: General Craving
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: A1c level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Digit Symbol Substitution Test (DSST): number of correct symbols
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: First urination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proportions of leukocyte subsets and thrombocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Concentrations of biochemical markers of severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PASI 75 Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Rate of ACR 50
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of The Disease Activity Score (DAS) 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with ≥ 1log10 reduction in HBsAg titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adequacy rate of surgical antimicrobial prophylaxis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of subjects experiencing adverse events after single ascending doses
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects experiencing adverse events after repeat doses
Endpoint domain: Adverse events/effects
Primary endpoint: Overall impairment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Repeat chest tube insertion within 30 days
Endpoint domain: Adverse events/effects
Primary endpoint: Thoracotomy on affected side within 30 days
Endpoint domain: Adverse events/effects
Primary endpoint: arthroplasty loosening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to spontaneous ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: embryo implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Body temperature measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to collect drinking information
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Efficacy of endoscopic management
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Safety of endoscopic management
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence Rate of Malignancies
Endpoint domain: Mortality/survival
Primary endpoint: Incidence Rate of Myocardial Infarction and Ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence Rate of Acquired Immunodeficiency Syndrome (AIDS)-Defining Opportunistic Infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence Rate of Liver Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence Rate of Liver Related Death
Endpoint domain: Mortality/survival
Primary endpoint: Incidence Rate of Rhabdomyolysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose area product in cGy.cm2 (DAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thalamic atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Central Venous Catheter Hubs With Internal Contamination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of treatment-emergent adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Plethysmographic Variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of variation in Indexed Stroke Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: atelectasis volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: total lung volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Leibowitz Social Anxiety Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Fear-potentiated startle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Treatment-Emergent Neuropathy Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Glucagon tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incidence of adverse events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of eligible participants completing the OEP
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Number of Participants With Inflammation of the Oral Mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants With Inflammation of the Esophageal Mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of Patients Meeting ACR20 Response Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Prevalence of cortical thickening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Prevalence of beaking
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Resolution of acute urticaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Necrotizing Enterocolitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Clinical Response at Week 16 (PCDAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Response at Week 16 (Mayo Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes